Older age, poor performance status and major comorbidities: How to treat high-risk patients with advanced nonsmall cell lung cancer

Current Opinion in Oncology

Volumn 24, Issue 2, 2012, Pages 130-136

  Aggarwal, Charu ^a   Langer, Corey J ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

advanced nonsmall cell lung cancer; elderly; poor performance status

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; ETOPOSIDE; GEMCITABINE; NAVELBINE; PACLITAXEL; PEMETREXED; PLATINUM; VASCULOTROPIN;

ADVANCED CANCER; AGED; CANCER CHEMOTHERAPY; CANCER SURVIVAL; COMORBIDITY; CONFIDENCE INTERVAL; DIARRHEA; HIGH RISK PATIENT; HISTOLOGY; HUMAN; LUNG NON SMALL CELL CANCER; META ANALYSIS (TOPIC); OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POST HOC ANALYSIS; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; COMORBIDITY; FEMALE; GERIATRICS; HUMANS; LUNG NEOPLASMS; MALE; PALLIATIVE CARE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE;

EID: 84856835072     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/CCO.0b013e32834ea6ea     Document Type: Review

References (53)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010; 60:277-300.
2. Ries LAG, Melbert D, Krapcho M, et al., editors. SEER Cancer Statistics Review, 1975-2005, National Cancer Institute. Bethesda, MD: National Cancer Institute. http://seer.cancer.gov/csr/1975-2005/.
3. Owonikoko TK, Ragin CC, Belani CP, et al. Lung cancer in elderly patients: An analysis of the surveillance, epidemiology, and end results database. J Clin Oncol 2007; 25:5570-5577.
4. Pallis AG, Karampeazis A, Vamvakas L et al. Efficacy and treatment tolerance in older patients with NSCLC: A meta-Analysis of five phase III randomized trials conducted by the hellenic oncology research group. Ann Oncol 2011; 22:2448-2455. Pooled data from five clinical trials of the Hellenic Oncology Research Group were analyzed; 424 patients (23%) were at least 70 years. There was a higher risk for death in older patients. However, when the analysis was carried out after omitting a trial that showed a different trend, no difference was observed. Older patients experienced higher toxicity.
5. Hotta K, Ueoka H, Kiura K, et al. An overview of 48 elderly-specific clinical trials of systemic chemotherapy for advanced nonsmall cell lung cancer. Lung Cancer 2004; 46:61-76. (Pubitemid 39201385)
6. Hutchins LF, Unger JM, Crowley JJ, et al. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 1999; 341:2061-2067. (Pubitemid 30035956)
7. Davidoff AJ, Tang M, Seal B, Edelman MJ. Chemotherapy and survival benefit in elderly patients with advanced nonsmall-cell lung cancer. J Clin Oncol 2010; 28:2191-2197.
8. Chrischilles EA, Pendergast JF, Kahn KL, et al. Adverse events among the elderly receiving chemotherapy for advanced nonsmall-cell lung cancer. J Clin Oncol 2009; 28:620-627.
9. Earle CC, Venditti LN, Neumann PJ, et al. Who gets chemotherapy for metastatic lung cancer? Chest 2000; 117:1239-1246. (Pubitemid 30321574)
10. Ramsey SD, Howlader N, Etzioni RD, Donato B. Chemotherapy use, outcomes, and costs for older persons with advanced nonsmall-cell lung cancer: Evidence from surveillance, epidemiology and end results-medicare. J Clin Oncol 2004; 22:4971-4978. (Pubitemid 46638623)
11. The elderly lung cancer vinorelbine italian study group. Effects of vinorelbine on quality of life and survival of elderly patients with advanced nonsmall-cell lung cancer. J Natl Cancer Inst 1999; 91:66-72.
12. Fidias P, Supko JG, Martins R, et al. A phase II study of weekly paclitaxel in elderly patients with advanced nonsmall cell lung cancer. Clin Cancer Res 2001; 7:3942-3949. (Pubitemid 34044612)
13. Kudoh S, Takeda K, Nakagawa K, et al. Phase III study of docetaxel compared with vinorelbine in elderly patients with advanced nonsmall-cell lung cancer: Results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904). J Clin Oncol 2006; 24:3657-3663. (Pubitemid 46630541)
14. Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with nonsmall-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004; 22:1589-1597. (Pubitemid 41079796)
15. Weiss GJ, Langer C, Rosell R, et al. Elderly patients benefit from second-line cytotoxic chemotherapy: A subset analysis of a randomized phase III trial of pemetrexed compared with docetaxel in patients with previously treated advanced nonsmall-cell lung cancer. J Clin Oncol 2006; 24:4405-4411. (Pubitemid 46630978)
16. Gridelli C, Perrone F, Gallo C, et al. Chemotherapy for elderly patients with advanced nonsmall-cell lung cancer: The multicenter italian lung cancer in the elderly study (MILES) phase III randomized trial. J Natl Cancer Inst 2003; 95:362-372. (Pubitemid 36395256)
17. Frasci G, Lorusso V, Panza N, et al. Gemcitabine plus vinorelbine yields better survival outcome than vinorelbine alone in elderly patients with advanced nonsmall cell lung cancer. a southern italy cooperative oncology group (SICOG) phase III trial. Lung Cancer 2001; 34 (Suppl 4):S65-S69.
18. Hainsworth JD, Spigel DR, Farley C, et al. Weekly docetaxel versus docetaxel/ gemcitabine in the treatment of elderly or poor performance status patients with advanced nonsmall cell lung cancer: A randomized phase 3 trial of the minnie pearl cancer research network. Cancer 2007; 110:2027-2034. (Pubitemid 350036863)
19. Bonomi P, Kim K, Fairclough D, et al. Comparison of survival and quality of life in advanced nonsmall-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: Results of an eastern cooperative oncology group trial. J Clin Oncol 2000; 18:623-631. (Pubitemid 30078543)
20. Langer CJ, Manola J, Bernardo P, et al. Cisplatin-based therapy for elderly patients with advanced nonsmall-cell lung cancer: Implications of eastern cooperative oncology group 5592, a randomized trial. J Natl Cancer Inst 2002; 94:173-181. (Pubitemid 34162751)
21. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced nonsmall-cell lung cancer. N Engl J Med 2002; 346:92-98. (Pubitemid 34438899)
22. Langer C, Vangel M, Schiller JH. Age-specific subanalysis of ECOG 1594: Fit elderly patients (70-80 YRS) with NSCLC do as well as younger pts (
23. Fossella F, Pereira JR, von Pawel J, et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced nonsmall-cell lung cancer: The TAX 326 study group. J Clin Oncol 2003; 21:3016-3024. (Pubitemid 46606280)
24. Belani CP, Fossella F. Elderly subgroup analysis of a randomized phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for first-line treatment of advanced nonsmall cell lung carcinoma (TAX 326). Cancer 2005; 104:2766-2774. (Pubitemid 41798287)
25. Ohe Y, Niho S, Kakinuma R, et al. A phase II study of cisplatin and docetaxel administered as three consecutive weekly infusions for advanced nonsmallcell lung cancer in elderly patients. Ann Oncol 2004; 15:45-50. (Pubitemid 38139602)
26. Tsukada H, Yokoyama A, Nishiwaki Y. Randomized controlled trial comparing docetaxel (D)-cisplatin (P) combination with D alone in elderly patients (pts) with advanced nonsmall cell lung cancer (NSCLC): JCOG0207. J Clin Oncol 2007; 25:18s (suppl; abstr 7629).
27. Abe T, Yokoyama A, Takeda K. Randomized phase III trial comparing weekly docetaxel (D)-cisplatin (P) combination with triweekly D alone in elderly patients (pts) with advanced nonsmall cell lung cancer (NSCLC): An intergroup trial of JCOG0803/WJOG4307L. J Clin Oncol 2011; 29 (suppl):abstr 7509. This study compared cisplatin-docetaxel combination with docetaxel alone (given q3 weeks) in chemotherapy-naive patients more than 70 years, with performance status 0-1. This study failed to demonstrate any advantage of the addition of weekly P to single-Agent D in first-line chemotherapy for elderly advanced NSCLC patients.
28. Lilenbaum RC, Herndon JE, 2nd, List MA, et al. Single-Agent versus combination chemotherapy in advanced nonsmall-cell lung cancer: The cancer and leukemia group B (study 9730). J Clin Oncol 2005; 23:190-196. (Pubitemid 41702638)
29. Guetz GD, Uzzan B, Nicolas P. Meta-Analysis of efficacy and safety of singleagent and doublet chemotherapy with or without platinum in advanced nonsmall cell lung cancer in the elderly. J Clin Oncol 2011; 29. Meta-Analysis of 12 studies included 2530 patients (mean age 74 years). One-year OS was significantly improved with doublet chemotherapy, specifically when including platinum, compared with single-Agent therapy. Hematological sideeffects were higher in the elderly.
30. BelaniCP,RamalingamS, PerryMC, et al.Randomized, phase III study ofweekly paclitaxel incombination with carboplatin versus standardevery-3- weeksadministration of carboplatin and paclitaxel for patients with previously untreated advanced nonsmall-cell lung cancer. J Clin Oncol 2008; 26:468-473. (Pubitemid 351171701)
31. Ramalingam S, Perry MC, La Rocca RV, et al. Comparison of outcomes for elderly patients treated with weekly paclitaxel in combination with carboplatin versus the standard 3-weekly paclitaxel and carboplatin for advanced nonsmall cell lung cancer. Cancer 2008; 113:542-546.
32. Quoix E, Zalcman G, Oster JP, et al. Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced nonsmall-cell lung cancer: IFCT-0501 randomised, phase 3 trial. Lancet 2011; 378:1079-1088. The first prospective trial to successfully compare platinum-based combination regimen to single agent chemotherapy in elderly patients (>70 years). Despite increased toxic effects, platinum-based doublet chemotherapy was associated with survival benefit compared with vinorelbine or gemcitabine monotherapy in elderly patients with NSCLC.
33. Socinski MA, Bondarenko IN, Karaseva NA. Survival results of a randomized, phase III trial of nab-paclitaxel and carboplatin compared with cremophorbased paclitaxel and carboplatin as first-line therapy in advanced nonsmall cell lung cancer. J Clin Oncol 2011; 29 (suppl):abstr 7551. A post-hoc analysis of a phase III trial comparing weekly nab-paclitaxel in combination with carboplatin to conventional combination paclitaxel-carboplatin at 3-week intervals demonstrated an improvedOS survival in patients 70 years of age or older receiving nab-paclitaxel.
34. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated nonsmall-cell lung cancer. N Engl J Med 2005; 353:123-132. (Pubitemid 41058344)
35. Bezjak A, Tu D, Seymour L, et al. Symptom improvement in lung cancer patients treated with erlotinib: Quality of life analysis of the national cancer institute of canada clinical trials group study br.21. J Clin Oncol 2006; 24:3831-3837. (Pubitemid 46630729)
36. Wheatley-Price P, Ding K, Seymour L, et al. Erlotinib for advanced nonsmallcell lung cancer in the elderly: An analysis of the national cancer institute of canada clinical trials group study BR.21. J Clin Oncol 2008; 26:2350-2357.
37. Jackman DM, Yeap BY, Lindeman NI, et al. Phase II clinical trial of chemotherapy-naive patients > or = 70 years of age treated with erlotinib for advanced nonsmall-cell lung cancer. J Clin Oncol 2007; 25:760-766. (Pubitemid 350002874)
38. Lee S, Rudd R, Khan I. Topical: Randomized phase III trial of erlotinib compared with placebo in chemotherapy-naive patients with advanced nonsmall cell lung cancer (NSCLC) and unsuitable for first-line chemotherapy. J Clin Oncol 2010; 28:15s (suppl; abstr 7504). Chemo-naive NSCLC patients (ECOG performance status 2/3 or performance status 0/1 unfit for platinum chemotherapy; stage IIIB/IV) were randomized to erlotinib plus BSC or placebo plus BSC. Overall, erlotinib and BSC did not improve OS, but there was some evidence of benefit for PFS.
39. Lilenbaum R, Axelrod R, Thomas S, et al. Randomized phase II trial of erlotinib or standard chemotherapy in patients with advanced nonsmall-cell lung cancer and a performance status of 2. J Clin Oncol 2008; 26:863-869. (Pubitemid 351398077)
40. Reck M, Von Pawel J, Fischer JR. Erlotinib versus carboplatin/vinorelbine in elderly patients (age 70 or older) with advanced nonsmall cell lung carcinoma (NSCLC): A randomized phase II study of the German Thoracic Oncology Working Group. J Clin Oncol 2010; 28:15s (suppl; abstr 7565). In this randomized phase II trial, elderly patients (70 years) with advanced NSCLC were randomized to erlotinib or carboplatin+vinorelbine. Chemotherapy had an increased efficacy compared with erlotinib alone in an unselected patient population.
41. Stinchcombe T, Bradford DS, B. LC. Preliminary results of a randomized phase II trial of first-line treatment of gemcitabine (G) versus erlotinib (E) versus gemcitabine and erlotinib (GE) in patients 70 years or older with advanced nonsmall cell lung cancer (NSCLC). J Clin Oncol 2010; 28:15s (suppl; abstr 7576).
42. Le Caer H, Barlesi F, Corre R. A multicenter phase II randomized study of docetaxel (D)/gemcitabine (G) weekly followed by erlotinib (E) after progression versus erlotinib followed by docetaxel/gemcitabine after progression in advanced nonsmall cell lung cancer (NSCLC) in fit elderly patients selected with a comprehensive geriatric assessment (CGA): Groupe Français de Pneumocancerologie (GFPC)0504. J Clin Oncol 2010; 28:15s (suppl; abstr 7536). In fit elderly patients (median age 75), chemotherapy followed by erlotinib at progression was numerically superior to the reverse combination.
43. Gridelli C, Ciardiello F, Feld R, et al. International multicenter randomized phase III study of first-line erlotinib (E) followed by second-line cisplatin plus gemcitabine (CG) versus first-line CG followed by second-line E in advanced nonsmall cell lung cancer (aNSCLC): The TORCH trial. J Clin Oncol 2010; 28:15s (suppl; abstr 7508). Study evaluating sequential use of erlotinib and chemotherapy; first-line erlotinib followed by chemotherapy at progression is inferior to the reverse standard one, in unselected patients with advanced NSCLC.
44. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of nonsmall-cell lung cancer to gefitinib. N Engl J Med 2004; 350:2129-2139. (Pubitemid 38637993)
45. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361:947-957.
46. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 2004; 304:1497-1500. (Pubitemid 38720929)
47. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from 'never smokers' and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 2004; 101:13306-13311. (Pubitemid 39209661)
48. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for nonsmall-cell lung cancer. N Engl J Med 2006; 355:2542-2550. (Pubitemid 44917502)
49. Ramalingam SS, Dahlberg SE, Langer CJ, et al. Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: Analysis of eastern cooperative oncology group trial 4599. J Clin Oncol 2008; 26:60-65.
50. Wakelee HA, Dahlberg SE, Brahmer JR. Increased benefit from bevacizumab (BEV) in younger women with advanced NSCLC on eastern cooperate oncology group (ECOG) E4599. J Thor Oncol 2008; 3 (suppl 4):S282, abstr 131.
51. Leighl NB, Zatloukal P, Mezger J et al. Efficacy and safety of bevacizumabbased therapy in elderly patients with advanced or recurrent nonsquamous nonsmall cell lung cancer in the phase III BO17704 study (AVAiL). J Thorac Oncol 2010; 5:1970-1976.
52. Crino L, Dansin E, Garrido P et al. Safety and efficacy of first-line bevacizumab-based therapy in advanced nonsquamous nonsmall-cell lung cancer (SAiL, MO19390): A phase 4 study. Lancet Oncol 2010; 11:733-740.
53. Borghaei H, Mehra R, Millenson MM. Phase II study of bevacizumab and erlotinib in treatment-naive elderly patients (older than age 65) with advanced nonsmall cell lung cancer (NSCLC). J Clin Oncol 2011; 29 (suppl):abstr 7548. Study of bevacizumab and erlotinib in an unselected population, more than 65 years of age, and this combination was demonstrated to be well tolerated, with an estimated median PFS of 6.6 months and estimated median OS of 14.1 months. More data including molecular profiling are awaited.